Pyxis Oncology reports positive updated Phase 1 MICVO data in head and neck cancer

 

Pyxis Oncology reports positive updated Phase 1 MICVO data in head and neck cancer, supporting advancement to pivotal Phase 3 Headliner trial

• MICVO monotherapy in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma, with Phase 3 Headliner trial planned mid-2027.
•  fell 13% after MICVO’s confirmed ORR slipped from 46% to 36%. Solid vs history, but neuropathy, a mid-2027 Phase 3 and cash weighed on shares. https://notreload.xyz/xy/micvo-response-rate-slipped-and-so-did-pyxs/

https://finviz.com/stock?t=PYXS&p=d